Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
With Gilotrif sales building over time, private Boehringer Ingelheim turns its focus to broad development program for its third-generation EGFR inhibitor olmutinib, with ambition to become a leader in lung cancer.
You may also be interested in...
Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts. At BIO, he outlined his strategy and goals.
Hanmi shares have gone on a wild roller coaster ride as bad news came after good. A day after it announced a huge licensing agreement with Genentech, the South Korean firm unveiled that Boehringer Ingelheim had decided to return rights to olmutinib, the EGFR inhibitor it licensed from Hanmi last July.
The German pharma agreed to pay up to €210m to investigate ViraTherapeutics' lead candidate, VSV-GP, alone and in combination, with an option to buy ViraTherapeutics depending on the outcome of Phase I studies.